You are here

Publications

Found 133 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is J  [Clear All Filters]
2022
Green SR, Davis SH, Damerow S, Engelhart CA, Mathieson M, Baragaña B, Robinson DA, Tamjar J, Dawson A, Tamaki FK et al..  2022.  Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs.. Nat Commun. 13(1):5992.
Walsh KF, Lee MHee, Brejt JA, Reust MJ, Juste MJean, Hilaire G, Pape JWilliam, Koenig S, Dupnik K.  2022.  Prevalence of HTLV-I Infection and Its Association with Tuberculosis among Patients at an Urban Clinic in Haiti.. Am J Trop Med Hyg. 106(5):1333-5.
Benjamin B, Goldgur Y, Jork N, Jessen HJ, Schwer B, Shuman S.  2022.  Structures of Fission Yeast Inositol Pyrophosphate Kinase Asp1 in Ligand-Free, Substrate-Bound, and Product-Bound States.. mBio. 13(6):e0308722.
Benjamin B, Goldgur Y, Jork N, Jessen HJ, Schwer B, Shuman S.  2022.  Structures of Fission Yeast Inositol Pyrophosphate Kinase Asp1 in Ligand-Free, Substrate-Bound, and Product-Bound States.. mBio. 13(6):e0308722.
2021
Pandey S, Singh A, Yang G, d'Andrea FB, Jiang X, Hartman TE, Mosior JW, Bourland R, Gold B, Roberts J et al..  2021.  Characterization of Phosphopantetheinyl Hydrolase from Mycobacterium tuberculosis.. Microbiol Spectr. 9(2):e0092821.
Schwer B, Garg A, Jacewicz A, Shuman S.  2021.  Genetic screen for suppression of transcriptional interference identifies a gain-of-function mutation in Pol2 termination factor Seb1.. Proc Natl Acad Sci U S A. 118(33)
Zhang H, Hsu H-C, Kahne SC, Hara R, Zhan W, Jiang X, Burns-Huang K, Ouellette T, Imaeda T, Okamoto R et al..  2021.  Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.. J Med Chem. 64(9):6262-6272.
Schrader SM, Botella H, Jansen R, Ehrt S, Rhee K, Nathan C, Vaubourgeix J.  2021.  Multiform antimicrobial resistance from a metabolic mutation.. Sci Adv. 7(35)
Beites T, Jansen RS, Wang R, Jinich A, Rhee KY, Schnappinger D, Ehrt S.  2021.  Multiple acyl-CoA dehydrogenase deficiency kills Mycobacterium tuberculosis in vitro and during infection.. Nat Commun. 12(1):6593.
Beites T, Jansen RS, Wang R, Jinich A, Rhee KY, Schnappinger D, Ehrt S.  2021.  Multiple acyl-CoA dehydrogenase deficiency kills Mycobacterium tuberculosis in vitro and during infection.. Nat Commun. 12(1):6593.
Harnagel A, Quezada LLopez, Park SWoong, Baranowski C, Kieser K, Jiang X, Roberts J, Vaubourgeix J, Yang A, Nelson B et al..  2021.  Nonredundant functions of Mycobacterium tuberculosis chaperones promote survival under stress.. Mol Microbiol. 115(2):272-289.
Saito K, Mishra S, Warrier T, Cicchetti N, Mi J, Weber E, Jiang X, Roberts J, Gouzy A, Kaplan E et al..  2021.  Oxidative damage and delayed replication allow viable Mycobacterium tuberculosis to go undetected.. Sci Transl Med. 13(621):eabg2612.
Antanasijevic A, Sewall LM, Cottrell CA, Carnathan DG, Jimenez LE, Ngo JT, Silverman JB, Groschel B, Georgeson E, Bhiman J et al..  2021.  Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.. Nat Commun. 12(1):4817.
Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, Francomano E, Klasse PJ, Moore JP, McDonough KA et al..  2021.  Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.. J Clin Endocrinol Metab. 106(5):e2025-e2034.
Jurgens EMatthew, Ketas TJoseph, Zhao Z, Satlin MJoseph, Small CButkus, Sukhu A, Francomano E, Klasse PJohan, Garcia A, Nguyenduy E et al..  2021.  Serologic response to mRNA COVID-19 vaccination in lymphoma patients.. Am J Hematol. 96(11):E410-E413.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..  2021.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..  2021.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Grover S, Engelhart CA, Pérez-Herrán E, Li W, Abrahams KA, Papavinasasundaram K, Bean JM, Sassetti CM, Mendoza-Losana A, Besra GS et al..  2021.  Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis.. ACS Infect Dis. 7(1):141-152.
Zhang L, Jiang X, Pfau D, Ling Y, Nathan CF.  2021.  Type I interferon signaling mediates Mycobacterium tuberculosis-induced macrophage death.. J Exp Med. 218(2)
2020
Zaveri A, Wang R, Botella L, Sharma R, Zhu L, Wallach JB, Song N, Jansen RS, Rhee KY, Ehrt S et al..  2020.  Depletion of the DarG antitoxin in Mycobacterium tuberculosis triggers the DNA-damage response and leads to cell death.. Mol Microbiol.
2019
Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, Ma X, Wei F.  2019.  CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions.. Cancer Immunol Immunother. 68(3):365-377.
Wu J, Mu R, Sun M, Zhao N, Pan M, Li H, Dong Y, Sun Z, Bai J, Hu M et al..  2019.  Derivatives of Natural Product Agrimophol as Disruptors of Intrabacterial pH Homeostasis in .. ACS Infect Dis. 5(7):1087-1104.
Quezada LLopez, Li K, McDonald SL, Nguyen Q, Perkowski AJ, Pharr CW, Gold B, Roberts J, McAulay K, Saito K et al..  2019.  Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating .. ACS Infect Dis. 5(8):1433-1445.
Wang C, Li Y, Chu C-M, Zhang X-M, Ma J, Huang H, Wang Y-N, Hong T-Y, Zhang J, Pan X-W et al..  2019.  Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma.. EBioMedicine. 39:255-264.
Wei F, Jiang Z, Sun H, Pu J, Sun Y, Wang M, Tong Q, Bi Y, Ma X, Gao GFu et al..  2019.  Induction of PGRN by influenza virus inhibits the antiviral immune responses through downregulation of type I interferons signaling.. PLoS Pathog. 15(10):e1008062.